209 related articles for article (PubMed ID: 23545288)
41. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir.
Seyfoddin A; Al-Kassas R
Drug Dev Ind Pharm; 2013 Apr; 39(4):508-19. PubMed ID: 22424312
[TBL] [Abstract][Full Text] [Related]
42. High-energy ball milling of saquinavir increases permeability across the buccal mucosa.
Rambharose S; Ojewole E; Branham M; Kalhapure R; Govender T
Drug Dev Ind Pharm; 2014 May; 40(5):639-48. PubMed ID: 24499179
[TBL] [Abstract][Full Text] [Related]
43. Cationic ligand appended nanoconstructs: a prospective strategy for brain targeting.
Agarwal A; Agrawal H; Tiwari S; Jain S; Agrawal GP
Int J Pharm; 2011 Dec; 421(1):189-201. PubMed ID: 21986113
[TBL] [Abstract][Full Text] [Related]
44. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement.
Sanjula B; Shah FM; Javed A; Alka A
J Drug Target; 2009 Apr; 17(3):249-56. PubMed ID: 19255893
[TBL] [Abstract][Full Text] [Related]
45. Protection of SK-N-MC cells against β-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin.
Kuo YC; Wang CT
Biomaterials; 2014 Jul; 35(22):5954-64. PubMed ID: 24746790
[TBL] [Abstract][Full Text] [Related]
46. Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin.
Abul Kalam M; Sultana Y; Ali A; Aqil M; Mishra AK; Aljuffali IA; Alshamsan A
J Biomed Mater Res A; 2013 Jun; 101(6):1813-27. PubMed ID: 23255511
[TBL] [Abstract][Full Text] [Related]
47. Multivariate Optimization of Rizatriptan Benzoate-Loaded Solid Lipid Nanoparticles for Brain Targeting and Migraine Management.
Girotra P; Singh SK
AAPS PharmSciTech; 2017 Feb; 18(2):517-528. PubMed ID: 27126007
[TBL] [Abstract][Full Text] [Related]
48. Targeted SLNs for management of HIV-1 associated dementia.
Rai A; Jain A; Jain A; Jain A; Pandey V; Chashoo G; Soni V; Sharma PR
Drug Dev Ind Pharm; 2015; 41(8):1321-7. PubMed ID: 25113430
[TBL] [Abstract][Full Text] [Related]
49. Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability.
Gupta S; Kesarla R; Chotai N; Misra A; Omri A
Biomed Res Int; 2017; 2017():5984014. PubMed ID: 28243600
[TBL] [Abstract][Full Text] [Related]
50. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel.
Liu Y; Li K; Pan J; Liu B; Feng SS
Biomaterials; 2010 Jan; 31(2):330-8. PubMed ID: 19783040
[TBL] [Abstract][Full Text] [Related]
51. Polyethyleneimine/poly-(γ-glutamic acid)/poly(lactide-co-glycolide) nanoparticles for loading and releasing antiretroviral drug.
Kuo YC; Yu HW
Colloids Surf B Biointerfaces; 2011 Nov; 88(1):158-64. PubMed ID: 21764569
[TBL] [Abstract][Full Text] [Related]
52. A novel anti-VEGF165 monoclonal antibody-conjugated liposomal nanocarrier system: physical characterization and cellular uptake evaluation in vitro and in vivo.
Shi C; Gao F; Gao X; Liu Y
Biomed Pharmacother; 2015 Feb; 69():191-200. PubMed ID: 25661357
[TBL] [Abstract][Full Text] [Related]
53. Chapter 1 - Drug delivery to the brain using colloidal carriers.
Chang J; Jallouli Y; Barras A; Dupont N; Betbeder D
Prog Brain Res; 2009; 180():2-17. PubMed ID: 20302826
[TBL] [Abstract][Full Text] [Related]
54. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration.
Xia H; Gao X; Gu G; Liu Z; Zeng N; Hu Q; Song Q; Yao L; Pang Z; Jiang X; Chen J; Chen H
Biomaterials; 2011 Dec; 32(36):9888-98. PubMed ID: 21937105
[TBL] [Abstract][Full Text] [Related]
55. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
Jain A; Agarwal A; Majumder S; Lariya N; Khaya A; Agrawal H; Majumdar S; Agrawal GP
J Control Release; 2010 Dec; 148(3):359-67. PubMed ID: 20854859
[TBL] [Abstract][Full Text] [Related]
56. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles.
Voigt N; Henrich-Noack P; Kockentiedt S; Hintz W; Tomas J; Sabel BA
Eur J Pharm Biopharm; 2014 May; 87(1):19-29. PubMed ID: 24607790
[TBL] [Abstract][Full Text] [Related]
57. Brain targeted solid lipid nanoparticles for brain ischemia: preparation and in vitro characterization.
Morsi NM; Ghorab DM; Badie HA
Pharm Dev Technol; 2013; 18(3):736-44. PubMed ID: 23477526
[TBL] [Abstract][Full Text] [Related]
58. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line.
Chattopadhyay N; Zastre J; Wong HL; Wu XY; Bendayan R
Pharm Res; 2008 Oct; 25(10):2262-71. PubMed ID: 18516666
[TBL] [Abstract][Full Text] [Related]
59. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations.
Vyas TK; Shahiwala A; Amiji MM
Int J Pharm; 2008 Jan; 347(1-2):93-101. PubMed ID: 17651927
[TBL] [Abstract][Full Text] [Related]
60. Solid lipid nanoparticles for delivery of andrographolide across the blood-brain barrier: in vitro and in vivo evaluation.
Graverini G; Piazzini V; Landucci E; Pantano D; Nardiello P; Casamenti F; Pellegrini-Giampietro DE; Bilia AR; Bergonzi MC
Colloids Surf B Biointerfaces; 2018 Jan; 161():302-313. PubMed ID: 29096375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
